DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis

Information source: CAMC Health System
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: MRSA Infections

Intervention: Ancef (Antibiotic Prophylaxis) (Drug); Vancomycin and Cefazolin (Antibiotic Prophylaxis) (Drug); Daptomycin and Cefazolin (Antibiotic Prophylaxis) (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: CAMC Health System

Official(s) and/or principal investigator(s):
Patrick Stone, M.D., Principal Investigator, Affiliation: CAMC Medical Staff-with admitting privileges

Summary

This study prospectively selects the patients to examine the effectiveness of the investigators' current standard of prophylaxis prior to vascular surgery and to compare the effectiveness of vancomycin and daptomycin plus cefazolin in reducing infections in vascular surgical patients.

Clinical Details

Official title: Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Primary outcome: To examine the effectiveness of our current standard of prophylaxis with Ancef.

Secondary outcome: To compare the effectiveness of vancomycin and daptomycin plus cefazolin in reducing infections in vascular surgical patients.

Detailed description: According to Medqic. org (site for the Surgical Care Improvement Project) the current recommended drug of choice for prophylaxis prior to vascular surgery is Cefazolin (Ancef). The exception would be to allow the use of Vancomycin as an acceptable antibiotic for patients undergoing cardiac, vascular or orthopedic surgery due to the increasing risk of MRSA. The significance of the study is to demonstrate that MRSA coverage is needed in vascular surgery with prosthetic graft placement in areas of the body that is at high risk for infection. By decreasing post surgical site and prosthetic infections, we could significantly reduce vascular surgery mortality and morbidity. Cost and amputation rates we feel could also be reduced. patients will be randomized in three groups such as cefazolin,vancomycin and cefazolin, daptomycin and cefazolin and then patients will be monitored per usual post-operative course (30 days and 90 days follow-up) with wound and incision evaluation. Outcome measures include hospital length of stay, the presence of a graft infection, skin infection at incision site, vascular procedure failure secondary to infection, cost, thirty day readmits, amputation, and mortality.

Eligibility

Minimum age: 18 Years. Maximum age: 90 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients greater than 18 years of age undergoing vascular surgery including carotid

procedures and a vascular access procedure (Fistula or Graft). Exclusion Criteria:

- Patients with an allergy to daptomycin or vancomycin.

- Patients with chronic wounds.

- Prior colonization of MRSA.

- Increased MRSA rate facility wide.

- Continuous inpatient stay >27 hrs prior to surgical procedure.

- Patients with active infection requiring antibiotics preoperatively.

- Patients with a history of MRSA colonization or infection, HIV, admission for >3

months in an acute care center or long-term care center, penicillin allergy or penicillin allergy and on dialysis.

- Dialysis patients.

Locations and Contacts

Vascular Center of Excellence, Charleston, West Virginia 25304, United States
Additional Information

Starting date: August 2007
Last updated: July 31, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017